InsiderSignal.AI

InsiderSignal.ai

MANE - Veradermics, Inc

Insider Purchase by Coric Vlad (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 weeks ago, Coric Vlad, serving as Dir at Veradermics, Inc (MANE), purchased 117,646 shares at $17.00 per share, for a total transaction value of $1,999,982.00. Following this transaction, Coric Vlad now holds 449,337 shares of MANE.

This purchase represents a 35.00% increase in Coric Vlad's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, February 5, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 5, 2026, meaning the disclosure happened on the same day as the trade.

Coric Vlad

Dir

Vlad Coric, M.D. is the Chairman and Chief Executive Officer of Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on developing therapies for neurological and neuropsychiatric diseases.[[1]](https://www.biohaven.com/wp-content/uploads/BIOHAVEN-Vlad-Coric-Bio-2022OCT03.pdf)[[5]](https://www.biohaven.com/about/our-people/meet-our-ceo/) With over 20 years of experience in drug discovery and clinical development at Yale School of Medicine and Bristol-Myers Squibb, Dr. Coric has led Biohaven since its early days as a startup, growing it from a $6 million pre-money valuation to a publicly traded company, culminating in its $13 billion acquisition of the CGRP portfolio by Pfizer in 2022.[[1]](https://www.biohaven.com/wp-content/uploads/BIOHAVEN-Vlad-Coric-Bio-2022OCT03.pdf)[[2]](https://www.cfgnh.org/vlac-coric)[[6]](https://www.biohaven.com/about/our-people/) Under his leadership, Biohaven achieved FDA approval and global launch of Nurtec ODT (rimegepant) for migraine treatment and filed an NDA for zavegepant, while expanding into international markets and pioneering digital-centric operations.[[1]](https://www.biohaven.com/wp-content/uploads/BIOHAVEN-Vlad-Coric-Bio-2022OCT03.pdf)[[3]](https://www.pharmavoice.com/news/biohaven-ceo-Vlad-Coric-Pfizer-Nurtec/642255/) Dr. Coric, whose father was a psychiatrist and mother a pharmacist, earned a Bachelor of Science in human physiology from the University of Connecticut and maintains an MD, serving as Associate Clinical Professor of Psychiatry at Yale.[[1]](https://www.biohaven.com/wp-content/uploads/BIOHAVEN-Vlad-Coric-Bio-2022OCT03.pdf)[[3]](https://www.pharmavoice.com/news/biohaven-ceo-Vlad-Coric-Pfizer-Nurtec/642255/)[[7]](https://coolidgefoundation.org/vlad-coric-m-d/) His career highlights include involvement in multiple drug programs across neuroscience, virology, oncology, and immuno-oncology, earning awards such as the Ernst & Young Entrepreneur of the Year 2018 in New York and Top 25 Healthcare Technology Leaders of Connecticut for 2022.[[1]](https://www.biohaven.com/wp-content/uploads/BIOHAVEN-Vlad-Coric-Bio-2022OCT03.pdf) As a recent corporate insider trader at Biohaven, Dr. Coric continues to drive innovation in treatments for conditions like epilepsy, OCD, and spinocerebellar ataxia.[[1]](https://www.biohaven.com/wp-content/uploads/BIOHAVEN-Vlad-Coric-Bio-2022OCT03.pdf)[[3]](https://www.pharmavoice.com/news/biohaven-ceo-Vlad-Coric-Pfizer-Nurtec/642255/)

View full insider profile →

Trade Price

$17.00

Quantity

117,646

Total Value

$1,999,982.00

Shares Owned

449,337

Trade Date

Thursday, February 5, 2026

17 days ago

SEC Filing Date

Thursday, February 5, 2026

About Veradermics, Inc

Company Overview

No company information available
View news mentioning MANE

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3730851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime